SRPA on targeted drug delivery and theranostics Cork Meeting

8/7/2019 SRPA on targeted drug delivery and theranostics Cork Meeting

http://slidepdf.com/reader/full/srpa-on-targeted-drug-delivery-and-theranostics-cork-meeting 1/13

Targeted drug deliveryby nanoparticles and

theranostics

SRPA Leader: Rafi KorensteinTel-Aviv UniversityE-mail: [email protected]



delivery routes

targetingnanocarriers



� Develop activity that will lead to the formationof long term research collaboration withindustry (e.g. initiation by STREP and IP in the7th Framework Program of EC followed byindustry supported research)

� Form an expertise reference point forindustry, research institutes and society

Strategic Goals



Scientific General Goals (1)

Development of new multifunctional targeted drugdelivery systems:

� Develop innovative nanoparticles and nanocapsules asdrug carrier systems for new drugs

� Examine novel approaches for enhancing the ability topass the cell/tissue barriers (mucosal lining, air-bloodbarrier of the human lung, blood-brain barrier)

� Explore novel targeting strategies (ppreferablycombined with bioimaging capacity of the targetedareas)



Scientific General Goals (2)

� Investigate ways for enhanced uptake of carriersfor intracellular targets.

� Development and validation of in-vitro modelsmimicking the in-vivo characteristics of human

tissues and organs for the examination of druguptake and toxicity aiming to limit in-vivo animaltesting.

� Theranostics (diagnostics & therapeutics) ²Integration of fast diagnostic devices and drugtherapy involving a feedback loop to monitor andimprove drug efficiency and to minimize sideeffects (individual therapy).



Specific Goals�

Cancer therapy - formation of integratedapproach to metastatic cancer therapy throughcombined chemotherapy linked to nanocarriersand electrical accelerated uptake of thechemotherapy in the primary tumor

� Active drug delivery ² MEMS/NEMS devicesfor regulated drug delivery (Microchip-baseddrug delivery consisting of microfluidicscombined with sensors

� Drug delivery of proteins and peptides

� Toxicology of nanaocarriers



Advantages of nanoparticles as drug carriers

Large surface-to-volume ratio resultingenhanced interaction sites

Surface functionalization for targeting

Suitable encapsulation

Release drugs in controlled manner

More efficient uptake by cells



Active drug delivery

MEMS/NEMS devices for regulated drug delivery(Microchip-based drug delivery consisting ofmicrofluidics combined with sensors

MEMS/NMEMS based devices

Release of drug (alone or associated with ananoparticle carrier)

Sensing (electrical, optical or chemical) enablingclosed loop drug delivery



Drug delivery by implantable nano/microdevices (semi implantable)

Development of 'smart' systems for the release oftherapeutic agents by devices placed at appropriatesites:

Concentration of therapeutic action exclusively orpredominantly at a desired target site (targeting)

Avoidance of barriers to the penetration therebyincrease the efficacy of the therapeutic action



Advantages of local drug release strategies

over systhemic drug therapy

� Lower doses required

� Greater control over toxicity and bioavailability of

dose� Extended duration of release

� Possibilities to combine local and systemic drugswith different kinetics

� Controlled release directly to site� Avoidance of systemic drug exposure





Limitations� Fully implantable devices are restricted in the

amount of drug to be released

� The requirement of surgical procedure forimplantation

� Biofouling/biocompatibility



Intersection ProjectsDuring the last annual meeting of N2L in Sitges (Barcellona)March 2006, the intersection on implantable drug deliverysystems was discussed. The need of targeting on specificclinically oriented goals was discussed in a forum consistingof about 20 participants. In view of this discussion andtaking into consideration the priorities of research in the

area of drug delivery in the field of nanomedicine it hasbeen decided to concentrate at present on two specificclinically oriented intersection topics:

Diabetes

Cancer therapy

More details on these two intersection projects are availableon the conference website.

Documents

SRPA on targeted drug delivery and theranostics Cork Meeting